Mitral Valve Regurgitation

Clinical Trial Finder

Many patients with mitral valve regurgitation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Myocardial Characterization of Arrhythmogenic Mitral Valve Prolapse (STAMP: STretch and Myocardial Characterization in Arrhythmogenic Mitral Valve Prolapse)

Condition:   Mitral Valve Prolapse
Intervention:   Device: Cardiac MRI
Sponsor:   Central Hospital, Nancy, France
Not yet recruiting - verified August 2016

Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects

Conditions:   HIV;   Diastolic Dysfunction;   Myocardial Fibrosis
Intervention:   Other: Cardiac MRI/MRS
Sponsors:   Massachusetts General Hospital;   President and Fellows of Harvard College
Recruiting - verified August 2016

ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)

Condition:   Cerebral Hemorrhage
Intervention:   Procedure: Early Surgical Hematoma Evacuation
Sponsors:   Nico Corporation;   Emory University
Not yet recruiting - verified August 2016

Neurothrombectomy France

Condition:   Cerebral Artery Occlusion
Intervention:  
Sponsor:   Nantes University Hospital
Completed - verified August 2016

Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event

Condition:   Post Stroke Recovery
Interventions:   Drug: S 44819 150 mg twice a day;   Drug: S 44819 300 mg twice a day;   Drug: Placebo
Sponsors:   Institut de Recherches Internationales Servier;   ADIR Association
Not yet recruiting - verified July 2016

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

Condition:   Diabetes Mellitus
Interventions:   Drug: Albiglutide 50mg;   Drug: Albiglutide matching placebo;   Drug: Exenatide 10microgram;   Drug: Exenatide placebo (saline)
Sponsors:   GlaxoSmithKline;   The General Hospital Corporation d/b/a Massachusetts General Hospital
Not yet recruiting - verified August 2016

Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis

Conditions:   Systematic Sclerosis;   Digital Ulcer;   Scleroderma
Intervention:   Drug: Bosentan group
Sponsor:   Elpen Pharmaceutical Co. Inc.
Not yet recruiting - verified May 2016

The DESappear Study: Drug Eluting Scaffold

Condition:   Peripheral Vascular Disease
Intervention:   Device: Akesys Prava Scaffold
Sponsors:   Elixir Medical Corporation;   Syntactx;   Massachusetts General Hospital
Not yet recruiting - verified August 2016

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

Condition:   Acute Ischemic Stroke
Interventions:   Drug: natalizumab;   Drug: Placebo
Sponsor:   Biogen
Recruiting - verified August 2016

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

Conditions:   Acute Ischemic Stroke;   Thrombotic Disease
Interventions:   Drug: DS-1040b;   Drug: placebo
Sponsor:   Daiichi Sankyo Inc.
Recruiting - verified August 2016

Magnetic Resonance Spectroscopy (MRS) in Midlife Depression

Conditions:   Depression;   Depression Bipolar
Intervention:  
Sponsor:   Emory University
Recruiting - verified June 2016

Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function

Conditions:   Alzheimer's Disease;   Obesity;   Diabetes Mellitus
Interventions:   Dietary Supplement: Boost A;   Behavioral: Healthy Living Diet
Sponsor:   National Institute on Aging (NIA)
Recruiting - verified August 2016

Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Condition:   Chronic Ischemic Stroke
Interventions:   Biological: SB623 Implant (2.5M);   Biological: SB623 Implant (5.0M);   Procedure: Sham surgery
Sponsors:   SanBio, Inc.;   Sunovion
Recruiting - verified June 2016

BestFIT: a Personalized Weight Loss Program

Condition:   Obesity
Interventions:   Behavioral: Behavioral weight loss therapy;   Behavioral: Meal replacements;   Behavioral: Enhanced behavioral weight loss therapy
Sponsors:   HealthPartners Institute;   Drexel University;   University of Michigan;   University of Minnesota - Clinical and Translational Science Institute;   University of Washington;   National Cancer Institute (NCI)
Recruiting - verified August 2016

Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan RCT

Condition:   Ischemic Stroke
Interventions:   Procedure: Rescue endovascular therapy;   Procedure: No endovascular therapy
Sponsor:   Shinichi Yoshimura
Terminated - verified August 2016

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Condition:   Scleroderma, Systemic
Interventions:   Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified August 2016

Investigating the Role of the Polyol Pathway in the Central Nervous System

Condition:   Hyperglycemia
Interventions:   Other: Brain MRS during hyperglycemic clamp;   Other: Analysis of Metabolites in cerebrospinal fluid
Sponsor:   Yale University
Recruiting - verified August 2016

Decompressive Hemicraniectomy in Intracerebral Hemorrhage

Condition:   Cerebral Hemorrhage
Interventions:   Procedure: Decompressive craniectomy (DC) and best medical treatment;   Procedure: Best medical treatment
Sponsor:   University Hospital Inselspital, Berne
Recruiting - verified August 2016

Tau Imaging of Chronic Traumatic Encephalopathy

Condition:   Chronic Traumatic Encephalopathy.
Interventions:   Radiation: [F18]-T807;   Radiation: [F18]-Florbetapir;   Device: MRI/MRS;   Genetic: Genetic Analysis for Genetic Risk Score for Tau.
Sponsors:   Marcelo F. Di Carli, MD, FACC;   U.S. Army Medical Research and Materiel Command;   Boston University
Enrolling by invitation - verified August 2016

PERIGON Pivotal Trial

Condition:   Aortic Stenosis
Intervention:   Device: Model 400 aortic valve bioprosthesis
Sponsors:   Medtronic Cardiovascular;   Medtronic
Recruiting - verified August 2016

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified August 2016

Cardioband With Transfemoral Delivery System

Condition:   Mitral Regurgitation
Intervention:   Device: Cardioband
Sponsor:   Valtech Cardio Ltd
Active, not recruiting - verified August 2016

NeoChord TACT Post-Market Surveillance Registry

Conditions:   Mitral Valve Insufficiency;   Heart Valve Diseases;   Heart Diseases;   Cardiovascular Diseases
Intervention:  
Sponsor:   NeoChord
Completed - verified August 2016

Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair

Condition:   Mitral Valve Insufficiency
Intervention:   Device: Cardioband adjustable band
Sponsor:   Valtech Cardio Ltd
Active, not recruiting - verified August 2016

7T MRS in Parkinson's Disease

Condition:   Parkinson's Disease
Intervention:  
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified August 2016

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

Condition:   Stroke
Interventions:   Drug: GM602;   Drug: Placebo Comparator
Sponsors:   Genervon Biopharmaceuticals, LLC;   University of California, Los Angeles;   Huntington Hospital;   Hoag Memorial Hospital Presbyterian;   Columbia University;   California Pacific Medical Center Research Institute;   University Hospital Erlangen;   Sarasota Memorial Hospital;   University of Louisville
Recruiting - verified August 2016

Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

Conditions:   Systemic Sclerosis;   Scleroderma
Intervention:   Drug: Ambrisentan
Sponsors:   University of Pennsylvania;   Gilead Sciences
Active, not recruiting - verified August 2016